Virax Biolabs | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Virax Biolabs | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Virax Biolabs | 6-K: Virax Biolabs Group Limited to Participate at ESCMID Global 2024
Virax Biolabs | 6-K: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
Virax Biolabs | SC 13G: Statement of acquisition of beneficial ownership by individuals-Armistice Capital, LLC(9.99%),Steven Boyd(9.99%)
Virax Biolabs | 6-K: Report of foreign private issuer (related to financial reporting)
Virax Biolabs | 424B5: Prospectus
Virax Biolabs | 6-K: Report of foreign private issuer (related to financial reporting)
Virax Biolabs | 6-K: Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in Covid Patients
Virax Biolabs | 424B3: Prospectus
Virax Biolabs | 6-K: Third Amended and Restated Memorandum of Association
Virax Biolabs | 424B3: Prospectus
Virax Biolabs | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Virax Biolabs | EFFECT: Others
Virax Biolabs | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Virax Biolabs | CORRESP: CORRESP
Virax Biolabs | UPLOAD: Others
Virax Biolabs | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Virax Biolabs | F-3: Registration statement for specified transactions by certain foreign private issuers
Virax Biolabs | 6-K: Report of foreign private issuer (related to financial reporting)
No Data